Tag: neuroprotection
“The race is on”: enthusiasm over neuroprotection endures despite historic failures
“The race is on—don’t miss the bus!”, were the words of David Liebeskind (University of California Los Angeles Health, Los Angeles, USA) as he...
Ox-01 neuroprotective candidate selected for evaluation in new US NINDS programme
FreeOx Biotech has announced that its uric acid-based leading compound, Ox-01, has been officially selected by the US National Institute of Neurological Disorders and...
Positive HEMERA-1 data pave the way for further neuroprotection trials during...
Following the recent publication in Stroke: Vascular and Interventional Neurology of results from HEMERA-1, a prospective, multicentre trial evaluating the safety of novel neuroprotective...
Silk Road adds Enroute NPS Plus device to TCAR portfolio
Silk Road Medical has announced the launch of its Enroute transcarotid neuroprotection system Plus (NPS Plus), which the company describes as a key component of...
Lumosa, CHI Memorial announce new studies of stroke drug combining clot-busting...
Lumosa Therapeutics, in collaboration with CHI Memorial (Chattanooga, USA), has announced the initiation of multiple Phase 2 clinical trials for LT3001, which the company...
Athersys announces ‘disappointing’ results from MASTERS-2 interim analysis
Athersys has announced that the independent data safety monitoring board (DSMB) has completed a preplanned interim analysis of the company’s ongoing, phase three MASTERS-2...
LINNC 2023 examines neuroprotection, steerable microcatheters and other ‘next frontiers’
Neuroprotective agents and steerable microcatheter technologies were among a number of potential new interventional neuroradiology (INR) frontiers showcased and discussed at this year’s LINNC...
AptaTargets announces publication of APRIL trial data in JAMA Neurology
As per a press release from AptaTargets, JAMA Neurology has published positive results from APRIL—a Phase 1b/2a clinical trial evaluating the safety and efficacy...
Combined neuroprotection therapy shows promise in experimental stroke model
A new study conducted by scientists at Louisiana State University (LSU) Health New Orleans Neuroscience Center of Excellence (New Orleans, USA) reports that the...
Astrocyte to initiate extended infusion Phase 1b study of cerebroprotective drug
Astrocyte Pharmaceuticals has announced the initiation of a Phase 1b study of its lead cerebroprotective candidate, AST-004, as an extended infusion in healthy volunteers....
Athersys announces changes to MASTERS-2 trial endpoints following US FDA meeting
Athersys has announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the US Food and Drug Administration (FDA)....
Uric acid-based neuroprotective agent demonstrates promise in large animal study
The opening day of the 2023 International Stroke Conference (ISC; 8–10 February, Dallas, USA) saw the presentation of findings from an animal-model study that...
Athersys granted clinical Type B meeting with US FDA to discuss...
Athersys, the company developing MultiStem (invimestrocel) cell therapy for critical care indications, announced recently that it has been granted a clinical Type B meeting with...
Celery seed derivative shows promise as neuroprotectant in acute ischaemic stroke
Ischaemic stroke patients treated with a clot-busting medication and/or mechanical thrombectomy who also received butylphthalide—a novel medication initially compounded from celery seed—experienced milder neurological...
Neuroprotective agent linked to reduced death and disability in ischaemic stroke...
ApTOLL, a neuroprotectant medication intended to shield the brain from tissue damage, has been linked to reduced death and disability when used alongside standard...
Neuroprotection “renaissance” offers hope for improved stroke therapies in future
The “renaissance” of neuro- and cerebroprotective paradigms, coupled with “the advent of new ideas”—such as the concept of ‘transient neuroprotection’ to preserve the penumbra—appears...
Athersys provides update on ischaemic stroke and haemorrhagic trauma trials of...
Athersys, the company developing MultiStem (invimestrocel)—an off-the-shelf stem cell treatment intended for critical care indications, including acute ischaemic stroke, trauma and other inflammatory conditions—has provided...
Shelley Renowden
Through her many years as a consultant neuroradiologist at the North Bristol NHS Trust (Bristol, UK), as well as organising the European Course in...
NoNO announces first patient dosed with NoNO-42 in Phase 1 study
NoNO Inc has announced the dosing of the first participant in its Phase 1 clinical trial evaluating NoNO-42—a next-generation neuroprotective drug developed in the...
LINNC 2021: ESCAPE-NEXT trial may bring “dream” of combining neuroprotection with...
At this year’s LINNC Paris Course (14–16 September, Paris, France and virtual), audiences heard that the ESCAPE-NEXT trial (sponsored by NoNO Inc.), which has already started enrolling...
Selective endovascular cooling with TwinFlo catheter shows promise for neuroprotection in...
Ron Solar (ThermopeutiX, San Diego, USA) and colleagues report in EuroIntervention that the TwinFlo catheter (ThermopeutiX), in pigs, was associated with rapid, selective, deep...
Combining reperfusion with neuroprotection: Reasons to reappraise the concept
“The main reason to reappraise the concept of neuroprotection in acute stroke is the of effective thrombectomy, which de facto has led to...
